公开(公告)号：US4868212A

公开(公告)日：1989-09-19

申请号：US307952

申请日：1989-02-09

Applicant: David F. Horrobin

Inventor： David F. Horrobin

IPC: A61K31/19 ,  A23D9/00 ,  A23L1/30 ,  A23L1/325 ,  A23L1/48 ,  A61K31/16 ,  A61K31/20 ,  A61K31/22 ,  A61K31/23 ,  A61K31/557 ,  A61K35/56 ,  A61K35/60 ,  A61K36/00 ,  A61K36/185 ,  A61K38/00 ,  A61P3/08 ,  A61P11/00 ,  A61P13/02 ,  A61P15/00 ,  A61P25/30 ,  A61P27/16 ,  A61P35/00 ,  A61P37/08

CPC classification number: A61K35/60 ,  A23D9/00 ,  A61K31/20 ,  A61K31/23 ,  A61K31/557 ,  A61K36/185 ,  Y10S514/861 ,  Y10S514/866

Abstract: A method of treatment of atopic disorders, including eczema, asthma, allergies (especially allergic rhinitis), migraine and disorders associated with atopy including Crohn's disease, ulcerative colitis, otitis media, nephrotic syndrome, or benign breast disease, or breast or other cancer, or diabetes, or alcoholism, with effective amounts of one or more of the metabolites of linoleic acid (GLA, DGLA, AA, 22:4n-6 or 22:5n-6) and one or more of the metabolites of .alpha.-linolenic acid (18:4n-3, 20:4n-3, 20:5n-3, 22:5n-3 or 22:6n-3) are administered as such or in the form of an ester, salt, amide or other derivative convertible in the body thereto alone or in an acceptable pharmaceutical carrier or diluent.

公开(公告)号：US4248872A

公开(公告)日：1981-02-03

申请号：US69493

申请日：1979-08-24

Applicant: David F. Horrobin

Inventor： David F. Horrobin

IPC: A61K31/415 ,  A61K31/505

CPC classification number: A61K31/415 ,  A61K31/505

Abstract: A method for the treatment of anxiety which consists of administering dipyridamole or imidazole or a derivative thereof. It has been found that known anti-anxiety agents appear to act as competitive antagonists of thromboxane A2 (TXA2), and it is therefore believed that dipyridamole and imidazole, which inhibit the formation of TXA2, will be effective in the treatment of anxiety.

Abstract translation: 治疗焦虑症的方法，其由施用双嘧达莫或咪唑或其衍生物组成。 已经发现已知的抗焦虑剂似乎作为血栓素A2（TXA2）的竞争性拮抗剂，因此认为抑制TXA2形成的双嘧达莫和咪唑在治疗焦虑方面是有效的。